Beads with functionalized material applied to them are exposed to an acoustic field to trap, retain or pass the beads. The beads may include or be free of ferro magnetic material. The beads may be biocompatible or biodegradable for a host. The size of the beads may vary over a range, and/or be heterogenous or homogenous. The composition of the beads may include high, neutral or low acoustic contrast material. The chemistry of the functionalized material may be compatible with existing processes. The acoustic field may be generated, for example, in an acoustic angled wave device or in an acoustic fluidized bed.

Methods and systems for controlling one or more pumps of a heart-lung-machine. An illustrative method may comprise receiving an actual flow rate of a pump, determining the actual flow rate is from a primary pump, determining an available amount of the actual flow rate of the primary pump that is available to one or more subordinate pumps, comparing the available amount of the actual flow rate of the primary pump to a sum of set flow rates of the one or more subordinate pumps, and operating the one or more subordinate pumps in a proactive control mode or a reactive control mode.

In one representative embodiment, a method of perfusing organs in a patient's body is provided. The method comprises isolating the visceral arteries and the visceral veins from blood circulating through the patient's heart and perfusing the visceral arteries, the visceral veins, and the abdominal organs with a perfusion fluid that is fluidly separated from the blood circulating through the patient's heart. While the visceral arteries and the visceral veins are isolated, and the visceral arteries, the visceral veins, and the abdominal organs are being perfused, the patient's blood is allowed to continue to circulate through the heart.

Described are devices and methods for use in connection with organ replacement or organ assist therapy in a patient.

A fluid separation device includes a centrifugal separator configured to receive a centrifugal separation chamber of a disposable fluid flow circuit, a pump system configured to convey a fluid into the centrifugal separation chamber and to remove a separated fluid component from the centrifugal separation chamber via an outlet, a color-based interface monitoring system configured to determine an interface position between separated fluid components continuously flowing through the centrifugal separation chamber based on dominant wavelength measurements of layers of separated fluid components during a centrifugal separation procedure, and a controller configured to measure the dominant wavelengths of the layers, calculate a duration as a color time for each measured dominant wavelength, set target color times, calculate error signals and calculate control signals to adjust the pump system to control the flow rate and interface position.

A device and method for separating whole blood includes flowing whole blood to a centrifuge, separating whole blood into blood components within the centrifuge, and flowing separated blood components out of the centrifuge. The device and method include a flow rate stoppage phase executed one or more times during the method. The flow rate stoppage phase includes (i) stopping the flow of whole blood to the centrifuge and stopping the flow of separated blood components out of the centrifuge; (ii) spinning the centrifuge at a selected rate; and (iii) after a selected time ending the flow rate stoppage phase and resuming the flow of whole blood to the centrifuge and the flow of separated blood components out of the centrifuge.

In vivo and ex vivo positionable filtration devices are provided that are functionalized to bind one or more therapeutic agents in blood flowing in a blood vessel.

Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Apparatus and methods for concentrating platelet-rich plasma is described herein. One variation may generally comprise a tube having a length and defining a channel within and one or more ports located at a proximal end of the tube and in fluid communication with the channel. A plunger may slidably translatable within the channel while forming a seal against an inner surface of the channel and a float may have a pre-selected density and defining a concave interface surface, wherein the float is slidably contained within the channel such that the concave interface surface is in apposition to the one or more ports.

The present disclosure describes a novel therapeutic apheresis system and, more specifically, methods and an apparatus for performing therapeutic apheresis. The present disclosure provides highly efficient methods for therapeutic apheresis that modulate the immune system, thereby resulting in treatment of one or more underlying immunological disease processes. In some embodiments, the disclosed methods return at least a portion of blood from an extracorporeal circuit to a patient in pulsatile flow, where the portion of blood that is returned is augmented. In other embodiments, the disclosed methods and apparatus use the central arterial system to exchange volumes of plasma to immunomodulate disease processes. The disclosed methods combine concepts of intermittent flow and continuous flow therapeutic apheresis with established cardiovascular concepts. In addition, the disclosed methods reduce the amount of time spent by patients in therapeutic apheresis sessions and decrease patients' dependence on immunological drugs that may have detrimental adverse effects.